These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Hori K; Saito S; Nihei Y; Suzuki M; Sato Y Jpn J Cancer Res; 1999 Sep; 90(9):1026-38. PubMed ID: 10551334 [TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and biological evaluation of combretastatin nitrogen-containing derivatives as inhibitors of tubulin assembly and vascular disrupting agents. Monk KA; Siles R; Hadimani MB; Mugabe BE; Ackley JF; Studerus SW; Edvardsen K; Trawick ML; Garner CM; Rhodes MR; Pettit GR; Pinney KG Bioorg Med Chem; 2006 May; 14(9):3231-44. PubMed ID: 16442292 [TBL] [Abstract][Full Text] [Related]
25. Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin a-4. Marrelli M; Conforti F; Statti GA; Cachet X; Michel S; Tillequin F; Menichini F Curr Med Chem; 2011; 18(20):3035-81. PubMed ID: 21651481 [TBL] [Abstract][Full Text] [Related]
26. Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs. implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062). Hori K; Saito S; Sato Y; Akita H; Kawaguchi T; Sugiyama K; Sato H Eur J Cancer; 2003 Sep; 39(13):1957-66. PubMed ID: 12932676 [TBL] [Abstract][Full Text] [Related]
28. Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. Hori K; Saito S; Sato Y; Kubota K Med Sci Monit; 2001; 7(1):26-33. PubMed ID: 11208488 [TBL] [Abstract][Full Text] [Related]
29. Combretastatins D-3 and D-4, new macrocyclic lactones from Getonia floribunda. Vongvanich N; Kittakoop P; Charoenchai P; Intamas S; Danwisetkanjana K; Thebtaranonth Y Planta Med; 2005 Feb; 71(2):191-3. PubMed ID: 15729632 [TBL] [Abstract][Full Text] [Related]
30. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Dark GG; Hill SA; Prise VE; Tozer GM; Pettit GR; Chaplin DJ Cancer Res; 1997 May; 57(10):1829-34. PubMed ID: 9157969 [TBL] [Abstract][Full Text] [Related]
31. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Kanthou C; Tozer GM Int J Exp Pathol; 2009 Jun; 90(3):284-94. PubMed ID: 19563611 [TBL] [Abstract][Full Text] [Related]
32. Synthesis and biological evaluation of novel 3,4-diaryl-1,2,5-selenadiazol analogues of combretastatin A-4. Guan Q; Yang F; Guo D; Xu J; Jiang M; Liu C; Bao K; Wu Y; Zhang W Eur J Med Chem; 2014 Nov; 87():1-9. PubMed ID: 25233100 [TBL] [Abstract][Full Text] [Related]
33. Recent advances in the field of tubulin polymerization inhibitors. Prinz H Expert Rev Anticancer Ther; 2002 Dec; 2(6):695-708. PubMed ID: 12503216 [TBL] [Abstract][Full Text] [Related]
34. OMA1520 and OMA1774, novel 1,2,4-triazole bearing analogs of combretastatin A-4, inhibit hepatocellular carcinoma: Histological and immunohistochemical studies. Nofal AE; Shatla IM; Abdelhafeez DA; Mustafa M; Aly OM Biomed Pharmacother; 2021 Jun; 138():111417. PubMed ID: 33752057 [TBL] [Abstract][Full Text] [Related]
35. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Chaplin DJ; Pettit GR; Hill SA Anticancer Res; 1999; 19(1A):189-95. PubMed ID: 10226542 [TBL] [Abstract][Full Text] [Related]
36. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Tozer GM; Prise VE; Wilson J; Cemazar M; Shan S; Dewhirst MW; Barber PR; Vojnovic B; Chaplin DJ Cancer Res; 2001 Sep; 61(17):6413-22. PubMed ID: 11522635 [TBL] [Abstract][Full Text] [Related]
37. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. McGown AT; Fox BW Anticancer Drug Des; 1989 Mar; 3(4):249-54. PubMed ID: 2930627 [TBL] [Abstract][Full Text] [Related]
38. Discovery of isoerianin analogues as promising anticancer agents. Messaoudi S; Hamze A; Provot O; Tréguier B; Rodrigo De Losada J; Bignon J; Liu JM; Wdzieczak-Bakala J; Thoret S; Dubois J; Brion JD; Alami M ChemMedChem; 2011 Mar; 6(3):488-97. PubMed ID: 21360820 [TBL] [Abstract][Full Text] [Related]
39. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Chaplin DJ; Pettit GR; Parkins CS; Hill SA Br J Cancer Suppl; 1996 Jul; 27():S86-8. PubMed ID: 8763854 [TBL] [Abstract][Full Text] [Related]
40. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours. Holwell SE; Cooper PA; Grosios K; Lippert JW; Pettit GR; Shnyder SD; Bibby MC Anticancer Res; 2002; 22(2A):707-11. PubMed ID: 12017147 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]